279 related articles for article (PubMed ID: 37920609)
1. Role of c-Myc in lung cancer: Progress, challenges, and prospects.
Wallbillich NJ; Lu H
Chin Med J Pulm Crit Care Med; 2023 Sep; 1(3):129-138. PubMed ID: 37920609
[TBL] [Abstract][Full Text] [Related]
2. Molecular genetics of small cell lung carcinoma.
Wistuba II; Gazdar AF; Minna JD
Semin Oncol; 2001 Apr; 28(2 Suppl 4):3-13. PubMed ID: 11479891
[TBL] [Abstract][Full Text] [Related]
3. lncRNAs as Potential Targets in Small Cell Lung Cancer: MYC -dependent Regulation.
Tokgun O; Tokgun PE; Inci K; Akca H
Anticancer Agents Med Chem; 2020; 20(17):2074-2081. PubMed ID: 32698750
[TBL] [Abstract][Full Text] [Related]
4. C-myc Contributes to Malignancy of Lung Cancer: A Potential Anticancer Drug Target.
Chanvorachote P; Sriratanasak N; Nonpanya N
Anticancer Res; 2020 Feb; 40(2):609-618. PubMed ID: 32014901
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of EGFR/mTOR/Nf-kb targeting small molecule for the treatment of non-small cell lung cancer.
Lawal B; Kuo YC; Wu AT; Huang HS
Am J Cancer Res; 2023; 13(6):2598-2616. PubMed ID: 37424807
[TBL] [Abstract][Full Text] [Related]
6. Different pattern of expression of cellular oncogenes in human non-small-cell lung cancer cell lines.
Kiefer PE; Wegmann B; Bacher M; Erbil C; Heidtmann H; Havemann K
J Cancer Res Clin Oncol; 1990; 116(1):29-37. PubMed ID: 1690210
[TBL] [Abstract][Full Text] [Related]
7. An overview of mortality & predictors of small-cell and non-small cell lung cancer among Saudi patients.
Alghamdi HI; Alshehri AF; Farhat GN
J Epidemiol Glob Health; 2018 Mar; 7 Suppl 1(Suppl 1):S1-S6. PubMed ID: 29801587
[TBL] [Abstract][Full Text] [Related]
8. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
[TBL] [Abstract][Full Text] [Related]
9. MYC, MYCL, and MYCN as therapeutic targets in lung cancer.
Massó-Vallés D; Beaulieu ME; Soucek L
Expert Opin Ther Targets; 2020 Feb; 24(2):101-114. PubMed ID: 32003251
[No Abstract] [Full Text] [Related]
10. Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation.
Henry RE; Barry ER; Castriotta L; Ladd B; Markovets A; Beran G; Ren Y; Zhou F; Adam A; Zinda M; Reimer C; Qing W; Su W; Clark E; D'Cruz CM; Schuller AG
Oncotarget; 2016 Sep; 7(36):57651-57670. PubMed ID: 27472392
[TBL] [Abstract][Full Text] [Related]
11. L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer.
Nau MM; Brooks BJ; Battey J; Sausville E; Gazdar AF; Kirsch IR; McBride OW; Bertness V; Hollis GF; Minna JD
Nature; 1985 Nov 7-13; 318(6041):69-73. PubMed ID: 2997622
[TBL] [Abstract][Full Text] [Related]
12. Novel Primary Human Cancer Stem-Like Cell Populations from Non-Small Cell Lung Cancer: Inhibition of Cell Survival by Targeting NF-κB and MYC Signaling.
Windmöller BA; Beshay M; Helweg LP; Flottmann C; Beermann M; Förster C; Wilkens L; Greiner JFW; Kaltschmidt C; Kaltschmidt B
Cells; 2021 Apr; 10(5):. PubMed ID: 33925297
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK
Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185
[TBL] [Abstract][Full Text] [Related]
14. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
15. Cell-substratum interactions mediate oncogene-induced phenotype of lung cancer cells.
Barr LF; Campbell SE; Penno MB; Ball DW; Baylin SB
Cell Growth Differ; 1996 Sep; 7(9):1149-56. PubMed ID: 8877096
[TBL] [Abstract][Full Text] [Related]
16. Lusianthridin targeting of lung cancer stem cells via Src-STAT3 suppression.
Bhummaphan N; Petpiroon N; Prakhongcheep O; Sritularak B; Chanvorachote P
Phytomedicine; 2019 Sep; 62():152932. PubMed ID: 31100681
[TBL] [Abstract][Full Text] [Related]
17. C-myc/miR-150/EPG5 axis mediated dysfunction of autophagy promotes development of non-small cell lung cancer.
Li H; Liu J; Cao W; Xiao X; Liang L; Liu-Smith F; Wang W; Liu H; Zhou P; Ouyang R; Yuan Z; Liu J; Ye M; Zhang B
Theranostics; 2019; 9(18):5134-5148. PubMed ID: 31410206
[No Abstract] [Full Text] [Related]
18.
Thongsom S; Racha S; Ei ZZ; Petsri K; Aksorn N; Chamni S; Panpuang V; Zou H; Chanvorachote P
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674871
[TBL] [Abstract][Full Text] [Related]
19. Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.
Zhu L; Chen Z; Zang H; Fan S; Gu J; Zhang G; Sun KD; Wang Q; He Y; Owonikoko TK; Ramalingam SS; Sun SY
Cancer Res; 2021 Sep; 81(18):4822-4834. PubMed ID: 34289988
[TBL] [Abstract][Full Text] [Related]
20. Attacking c-Myc: targeted and combined therapies for cancer.
Huang H; Weng H; Zhou H; Qu L
Curr Pharm Des; 2014; 20(42):6543-54. PubMed ID: 25341931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
